Received Oct 23, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 7NX57 | — |
received a pediatric dose of Engerix B instead of the adult formulation; received a pediatric dose of Engerix B instead of the adult formulation; This non-serious case was reported by a nurse via call center representative and described the occurrence of adult use of a child product in a 45-year-old male patient who received HBV (Engerix B pediatric) (batch number 7NX57, expiry date 12-DEC-2026) for prophylaxis. On 07-SEP-2025, the patient received Engerix B pediatric. On 07-SEP-2025, an unknown time after receiving Engerix B pediatric, the patient experienced adult use of a child product (Verbatim: received a pediatric dose of Engerix B instead of the adult formulation) and underdose (Verbatim: received a pediatric dose of Engerix B instead of the adult formulation). The outcome of the adult use of a child product and underdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 07-OCT-2025 The Vaccine Administration Facility is the same as Primary Reporter A registered nurse reported that a patient received a pediatric dose of Engerix B instead of the adult formulation The nurse requested for medical information. Upon internal review the case was updated on 07-OCT-2025 The Suspect product was updated from Engerix 10mcg to Engerix B pediatric.